STOCK TITAN
  1. Home
  2. News
  3. ORGO

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Organogenesis Holdings Inc. (ORGO) to participate in the BTIG Snowbird MedTech Conference without a formal presentation.
Positive
  • None.
Negative
  • None.

CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held at the Cliff Lodge in Snowbird, UT from February 13th-14th.

Management will participate in 1x1 meetings on Wednesday, February 14th. There will be no formal presentation.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.


Organogenesis Holdings Inc. will participate in the BTIG Snowbird MedTech Conference from February 13th-14th, with 1x1 meetings scheduled for February 14th.

Organogenesis Holdings Inc. is a regenerative medicine company specializing in product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.

The BTIG Snowbird MedTech Conference will be held at the Cliff Lodge in Snowbird, UT.
Stock ORGO logo
Organogenesis Holdings Inc

NASDAQ:ORGO

ORGO Rankings

#3383 Ranked by Market Cap
#4077 Ranked by Stock Gains
N/A Ranked by Dividends

ORGO Latest News

Apr 16, 2024
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
Feb 29, 2024
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
Feb 8, 2024
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
Nov 9, 2023
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
Oct 5, 2023
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

ORGO Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Finance, Financial Conglomerates
US
Canton

About ORGO

headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.